# Accellix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accellix

- Industry: Biotechnology
- Headquarters: San Jose, US
- Website: www.accellix.com
- Total disclosed funding: $9.5M
- Latest round: Series D (Jun 11, 2020)
- Investors on record: 2

## About

Accellix, Inc. specializes in automating cell phenotyping solutions tailored for the GMP manufacturing environment, enhancing efficiency and accuracy in biotech and pharmaceutical applications.Accellix, Inc. was founded in 2007 and is headquartered in San Jose, US. The company operates in the cell therapy sector, providing advanced solutions for quality control during manufacturing. The firm raised USD 10.00 mn in venture funding in December 2021, led by BroadOak Capital Partners, bringing its total raised to USD 10.00 mn. CEO Nir Nimrodi leads the company through its strategic initiatives and recent funding efforts.Accellix offers an automated cell phenotyping platform designed for the GMP manufacturing environment. Its flagship product, the Accellix Instrument, combines automated sample preparation, flow cytometry, and extensive data analysis into a compact benchtop system. Utilizing a microfluidic cartridge and unitized dried reagents, the platform ensures reproducibility and accuracy while reducing manual handling. It provides customizable assays that meet critical QC requirements for clients in the cell therapy sector, marketed predominantly in North America and Europe.Accellix generates revenue through B2B transactions with biotechnology and pharmaceutical companies focused on cell and gene therapy. Their revenue model relies on sales of the Accellix Instrument and necessary consumables, such as microfluidic cartridges and reagents, through agreements that can involve one-time purchases or recurring orders required for ongoing operations in GMP environments, supporting the rising demand for automation in quality control processes.Following its recent funding of USD 10.00 mn in December 2021, Accellix plans to accelerate its commercial and development efforts. The company aims to expand its product offerings, although specific upcoming launches have not been disclosed. Additionally, Accellix is targeting expansion into new geographic markets to broaden its reach in the cell therapy sector, with strategic plans set to be implemented in the coming years.

## Funding rounds

- Series D, Jun 11, 2020, $9.5M — Axcel, bioMérieux

## Investors

- Axcel (https://capitalatlas.ai/funds/axcel) — Series D
- bioMérieux — Series D